Skip to main content
04/05/2023

Vall d'Hebron participates in a guide of recommendations for clinical trials with drug combinations for childhood cancer

Dr. Lucas Moreno

Dr. Lucas Moreno

04/05/2023

Dr. Lucas Moreno is the first author of the international work that presents a series of considerations for early phase studies with the aim of accelerating the arrival of new therapies to patients.

Dr. Lucas Moreno, head of the Pediatric Oncology and Hematology Service at Vall d'Hebron University Hospital and of the Childhood Cancer and Hematologic Diseases group at Vall d'Hebron Research Institute (VHIR), has participated in a global consensus document on recommendations for conducting early phase clinical trials with drug combinations for the treatment of pediatric cancer. This is a joint work between clinicians, statisticians, regulatory experts and patient experts from Europe and North America and is published in Journal of Clinical Oncology.

The development of new therapies for children with cancer is essential to improve patient outcomes and reduce short- and long-term side effects. Previous experience suggests that the use of several agents simultaneously may be more effective than treatment with a single drug, and may help to avoid resistance. To evaluate potential drug combinations, an international paper presents a consensus document to maximize the efficiency of early-stage clinical trials being conducted. "The goal is to make a rapid and efficient assessment to evaluate drug combinations without compromising safety or increasing toxicity. In this way, we hope to accelerate the arrival of new therapies to patients", says Dr. Moreno. Currently, 287 early clinical trials of drug combinations for pediatric cancer are underway.

The authors argue that there is interest in platform clinical trials, in which different drug combinations can be studied at the same time and the differences compared to monotherapy with standard treatment can be analyzed. It is also recommended that phase I and phase II be carried out at the same time in order to achieve faster results and, at the same time, reduce the resources required. It is also encouraged that a few patients be included initially in order to determine safe doses and to know early on whether it is appropriate to continue with the treatment.

Although the aim of trials is to answer a scientific question about the efficacy and safety of treatments, it is necessary to consider that patients participate in this type of study in the hope that it may also benefit them directly. This is why it is essential to make a good selection of patients and to use doses that are expected to have good results. In relation to the dose, it is recommended that it be adjusted according to that used in adults and patient body surface.

Finally, the work emphasizes the inclusion of the voice of patients and their families, as well as taking into account regulatory experts from the beginning of the cynical development of pediatric cancer treatments.

"The goal is to make a rapid and efficient assessment to evaluate drug combinations without compromising safety or increasing toxicity", says Dr. Lucas Moreno.

Related news

On World Cancer Research Day, we highlight the oncology research model of the Vall d'Hebron Campus that allows laboratory results to be transferred as quickly as possible to clinical practice.

This initiative has several collaborative projects with the aim of increasing knowledge about rare blood diseases and improving patient care.

The multicenter phase 1 trial has been conducted in patients aged 2 to 21 years with solid tumors unresponsive to standard treatments or in relapse.

Related professionals

Lucas Moreno Martín-Retortillo

Lucas Moreno Martín-Retortillo

Head of group
Childhood Cancer and Blood Disorders
Read more
Thaïs Murciano Carrillo

Thaïs Murciano Carrillo

Childhood Cancer and Blood Disorders
Read more
Roberta Antonelli

Roberta Antonelli

Main researcher
Childhood Cancer and Blood Disorders
Read more
Marina Ortiz Palacios

Marina Ortiz Palacios

Predoctoral researcher
Childhood Cancer and Blood Disorders
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.